Anavex Life Sciences Corp (AVXL)

[kevindenver]

“ANAVEX 2-73 (blarcamesine) demonstrated dose-dependent efficacy for both motor impairment (MDS-UPDRS) and cognition … which correlated with SIGMAR1 mRNA as a pharmacodynamic biomarker, respectively,” said Christopher Missling, PhD, president & CEO of Anavex.

https://parkinsonsnewstoday.com/2022/03/17/anavex-2-73-high-dose-improves-pdd-patients-subscores-mds-updrs-phase-2-trial-update/

I understand the need to play devil's' advocate, but...I was able to find a statement regarding dose-dependency in PDD. Upon larger trials I bet Rett will display similar results.

The lack of dose effect is disappointing, but it's not the end of the world and the company's credibility by not making such claims is good to see. And see what they do claim shows dose dependency.